Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit?

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.01060
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Management of Borderline Resectable Pancreatic Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

Cutting‐edge Strategies for Borderline Resectable Pancreatic Cancer

Annals of Gastroenterological Surgery
2019English

Preoperative Nomogram to Predict Survival for Patients With Resectable and Borderline Resectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2017English

Meta-Analysis Comparing Upfront Surgery With Neoadjuvant Treatment in Patients With Resectable or Borderline Resectable Pancreatic Cancer

British Journal of Surgery
Surgery
2018English

Outcomes With FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer

Journal of Surgical Oncology
MedicineSurgeryOncology
2013English

Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy

Annals of Surgical Oncology
OncologySurgery
2010English

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Medicine
2020English

Resectable Pancreatic Cancer Needs Surgery, Then Chemotherapy

BMJ
2004English

Erratum To: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival

Annals of Surgical Oncology
OncologySurgery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy